**INTRODUCTION:** DWP-450 is a 900 kDa botulinum toxin type A produced by *Clostridium botulinum*.

**OBJECTIVE:** To demonstrate the safety and efficacy of DWP-450 for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adult subjects.

**DESIGN:** Two identical double-blind placebo-controlled 150-day single-dose Phase III studies (EV-001 and EV-002) conducted at a total of 20 U.S. centers.

**METHODS:** Study subjects were at least 18 years of age and had moderate (GLS=2) to severe (GLS=3) glabellar lines at maximum frown, on the 4-point photonumeric Glabellar Line Scale (GLS, 0=no lines, 1=mild, 2=moderate, 3=severe). Subjects were randomly assigned in a 3:1 ratio to receive a single treatment (0.1 mL injected into each of 5 target sites in the glabellar region) of either DWP-450 (total of 20 U, administered as 4 U/0.1 mL) or Placebo (0.9% saline). Subjects were then followed for 150 days. The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. This was a composite endpoint based on both the Investigator and subject's assessments of glabellar lines at maximum frown on the GLS; a subject was a responder only if both independently agreed that a ≥2 point improvement had occurred from Day 0 to Day 30. Safety was evaluated throughout the study.

**RESULTS:** 330 subjects participated in the EV-001 study; 324 participated in EV-002.

For the primary efficacy endpoint, in EV-001 and EV-002 the percentages of responders in each of the Placebo and DWP-450 groups were 1.2% and 67.5%, and 1.3% and 70.4% respectively; the absolute difference between groups was 66.3% (p\<0.001) and 69.1%(p\<0.001) respectively.

Also at Day 30, as assessed by the Investigator using the Global Aesthetic Improvement Scale, in EV-001 and EV-002 the proportion of responders was 95.8% and 92.9% respectively.

In total, for each of EV-001 and EV-002: 38.2% of DWP-450 subjects and 32.1% of Placebo subjects, and 28.5% of DWP-450 subjects and 26.9% of Placebo subjects respectively, experienced one or more adverse events.

**CONCLUSION:** The results of these two parallel US phase III studies successfully met the predefined primary endpoint.
